세계의 호흡기 질환 백신 시장 : 부문별 예측(2025-2030년)

The Respiratory Disease Vaccine Market was valued at USD 23.42 billion in 2023, expected to reach USD 24.78 billion in 2024, and is projected to grow at a CAGR of 5.87%, to USD 34.93 billion by 2030.

The scope and definition of the respiratory disease vaccine market encompass the development, production, and distribution of vaccines aimed at preventing diseases affecting the respiratory system, such as influenza, COVID-19, and respiratory syncytial virus (RSV). The necessity of these vaccines is underscored by the persistent global burden of respiratory illnesses, which cause significant morbidity and mortality, impacting public health systems and economies. The application of respiratory vaccines is robust, involving both pediatric and adult populations, and spans both seasonal vaccination campaigns and outbreak response initiatives. End-use scope primarily covers healthcare institutions, including hospitals and clinics, and extends to government vaccination programs and individual consumers.

Market growth is driven by factors such as increasing awareness about preventive healthcare, advances in vaccine technologies, and governmental support for vaccination programs. The ongoing COVID-19 pandemic has further accelerated investments and research in this sector, providing potential opportunities for innovations like mRNA vaccines and intranasal delivery systems. Companies should focus on collaborative research partnerships and leveraging data analytics for effective market penetration strategies. However, market growth faces challenges like high development costs, regulatory hurdles, and vaccine hesitancy among populations. Maintaining supply chain integrity and addressing storage and distribution logistics also pose significant limitations.

To capitalize on these opportunities, businesses can invest in areas like the development of universal vaccines that offer broader protection and the integration of artificial intelligence for predictive modeling in vaccine efficacy and distribution optimization. Innovation in cold chain logistics and exploring plant-based and host-vector systems for vaccine production are promising research areas for future growth. The market is dynamic, with a multidisciplinary nature that spans biotechnology, medical science, and data analytics, requiring a harmonized approach for success. Companies that effectively address the rising demand, technological advancements, and regulatory compliance will be strategically positioned to thrive in the rapidly evolving respiratory disease vaccine market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Disease Vaccine Market

The Respiratory Disease Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of respiratory disorders
  • Clinical trials and vaccines developments in pipeline
  • Government initiatives supporting respiratory health
• Market Restraints
  • Lack of inadequate delivery infrastructure & limited awareness
• Market Opportunities
  • Increasing R&D expenditure by leading companies
  • Increase vaccine availability through reselling collaborations
• Market Challenges
  • Consumer trust & confidence in respiratory disease vaccination

Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Disease Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Disease Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Respiratory Disease Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Disease Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Disease Vaccine Market

A detailed market share analysis in the Respiratory Disease Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Disease Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Disease Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Respiratory Disease Vaccine Market

A strategic analysis of the Respiratory Disease Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Disease Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astrazeneca PLC, Bavarian Nordic A/S, Bharat Biotech International Ltd., CanSino Biologics Inc., Emergent BioSolutions, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Pfizer Inc., Sanofi S.A., Seqirus USA Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., and Vaxine Pty Ltd..

Market Segmentation & Coverage

This research report categorizes the Respiratory Disease Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Infection, market is studied across Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis.
• Based on Type, market is studied across Bacterial Vaccine, Combination Vaccine, and Viral Vaccine.
• Based on Age Group, market is studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of respiratory disorders
    • 5.1.1.2. Clinical trials and vaccines developments in pipeline
    • 5.1.1.3. Government initiatives supporting respiratory health
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of inadequate delivery infrastructure & limited awareness
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing R&D expenditure by leading companies
    • 5.1.3.2. Increase vaccine availability through reselling collaborations
  • 5.1.4. Challenges
    • 5.1.4.1. Consumer trust & confidence in respiratory disease vaccination
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Respiratory Disease Vaccine Market, by Infection

• 6.1. Introduction
• 6.2. Influenza Virus
• 6.3. Pertussis
• 6.4. Streptococcus Pneumoniae
• 6.5. Tuberculosis

7. Respiratory Disease Vaccine Market, by Type

• 7.1. Introduction
• 7.2. Bacterial Vaccine
• 7.3. Combination Vaccine
• 7.4. Viral Vaccine

8. Respiratory Disease Vaccine Market, by Age Group

• 8.1. Introduction
• 8.2. Adolescent Vaccination
• 8.3. Adult Vaccination
• 8.4. Infant Vaccination

9. Americas Respiratory Disease Vaccine Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Respiratory Disease Vaccine Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Disease Vaccine Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astrazeneca PLC
• 2. Bavarian Nordic A/S
• 3. Bharat Biotech International Ltd.
• 4. CanSino Biologics Inc.
• 5. Emergent BioSolutions, Inc.
• 6. GlaxoSmithKline PLC
• 7. Johnson & Johnson Services, Inc.
• 8. Merck & Co., Inc.
• 9. Moderna, Inc.
• 10. Pfizer Inc.
• 11. Sanofi S.A.
• 12. Seqirus USA Inc.
• 13. Serum Institute of India Pvt. Ltd.
• 14. Sinovac Biotech Ltd.
• 15. Vaxine Pty Ltd.